HCV Treatment in 2016: Genotypes 1, 2, and 3

Objectives

  • List available HCV direct acting antivirals (DAAs) available for HCV therapy in 2016
  • Describe appropriate HCV DAA therapies for HCV genotypes 1, 2, and 3
  • Evaluate the potential for DAA drug-drug interactions, particularly with HIV antiretroviral therapy.

Presented by:

Cody Chastain, MD
Assistant Professor, Viral Hepatitis Program
Vanderbilt University School of Medicine, Division of Infectious Diseases

Check all that apply
Check all that apply
By submitting this form, you accept the Mollom privacy policy.

Add comment

Log in to post comments